Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Stock Purchase Agreements (Narrative) (Details)

v3.23.1
Collaboration and Stock Purchase Agreements (Narrative) (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
Feb. 03, 2023
USD ($)
Jan. 27, 2023
shares
Oct. 11, 2022
USD ($)
Feb. 24, 2021
USD ($)
Milestone
Nov. 12, 2018
Oct. 31, 2021
Feb. 28, 2019
USD ($)
$ / shares
shares
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Collaboration revenue               $ 181 $ 577
Caelum | AstraZeneca                  
Deconsolidation of consolidated partner company, percentage deconsolidated           100.00%      
Cyprium | Sentnyl                  
Upfront fees payment       $ 8,000          
Payments of milestones       $ 12,000          
Number of development milestones | Milestone       2          
Collaboration revenue               $ 200 $ 600
Avenue                  
Sale of stock, number of shares issued | shares   448,000              
Avenue | InvaGen                  
Payments of milestones $ 200                
Percentage of shares repurchased     100.00%            
Purchase price of shares repurchased     $ 3,000            
Percentage of contingent fee payable     7.50%            
Contingent fee payable from proceeds of future financing     $ 4,000            
SPMA | Avenue | InvaGen                  
Sale of stock, ownership percentage after the transaction         33.30%        
FDA approval of the NDA | Cyprium | Sentnyl | Maximum                  
Payments of milestones       $ 255,000          
Strategic Transaction, First Stage | SPMA | Avenue | InvaGen                  
Sale of stock, ownership percentage after the transaction             33.30%    
Sale of stock, number of shares issued | shares             400,000    
Stock offering, price per share | $ / shares             $ 90.00    
Sale of Stock, Consideration Received on Transaction             $ 35,000